A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins

Tatiana Zdobnova; Evgeniya Sokolova; Oleg Stremovskiy; Dmitry Karpenko; William Telford; Ilya Turchin; Irina Balalaeva; Sergey Deyev

doi:10.18632/oncotarget.5130

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins

Tatiana Zdobnova, Evgeniya Sokolova, Oleg Stremovskiy, Dmitry Karpenko, William Telford, Ilya Turchin, Irina Balalaeva and Sergey Deyev _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:30919-30928. https://doi.org/10.18632/oncotarget.5130

Metrics: PDF 1621 views | HTML 2357 views | ?

Abstract

Tatiana Zdobnova1, Evgeniya Sokolova1, Oleg Stremovskiy2, Dmitry Karpenko2, William Telford3, Ilya Turchin4, Irina Balalaeva1, Sergey Deyev1,2

1Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod 603950, Russia

2Institute of Bioorganic Chemistry of The Russian Academy of Sciences, Moscow 117997, Russia

3National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

4Institute of Applied Physics of The Russian Academy of Sciences, Nizhny Novgorod, 603950 Russia

Correspondence to:

Sergey Deyev, e-mail: [email protected]

Keywords: xenograft tumor model, far-red fluorescent protein, ovarian carcinoma, HER2, immunotoxin

Received: April 15, 2015 Accepted: August 24, 2015 Published: September 05, 2015

ABSTRACT

We have created a novel fluorescent model of a human ovarian carcinoma xenograft overexpressing receptor HER2, a promising molecular target of solid tumors. The model is based on a newly generated SKOV-kat cell line stably expressing far-red fluorescent protein Katushka. Katushka is most suitable for the in vivo imaging due to an optimal combination of high brightness and emission in the “window of tissue transparency”. The relevance of the fluorescent model for the in vivo monitoring of tumor growth and response to treatment was demonstrated using a newly created HER2-targeted recombinant immunotoxin based on the 4D5scFv antibody and a fragment of the Pseudomonas exotoxin A.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5130

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins

Abstract